Singular Genomics Systems Inc - OMIC Net earnings per share (EPS TTM)
High barriers to entry and G4 patents protect the margins of Singular Genomics Systems (OMIC) from new entrants. The annual net income per share TTM growth trend on the GURU.Markets chart demonstrates a price vector where -2.00 captures the magnitude of this parameter. Singular Genomics Systems (OMIC) wins the competition through analysis speed, while stable equipment sales are ensured by the delivery of sequencing systems to research centers.
Singular Genomics Systems Inc - analytical breakdowns and key metrics (OMIC)
- share price and expert price forecast:
- issuer market value details:
- shareholders' equity book value data:
- debt and liquidity data:
Debt to Capital Ratio Singular Genomics Systems|OMIC - Long-Term Debt to Capital|Current Liabilities to Capital Singular Genomics Corp|OMIC - Company Debts|Debt to Book Value Ratio Singular Genomics Systems, Inc.|OMIC - Company Long-Term Debt|Short-Term Debt Singular Genomics|Quick Liquidity Indicator singulargenomics.com
- financial results and valuation multiples details:
OMIC - Net Profit|Company Profit Forecast Singular Genomics Systems|OMIC - P/E Multiple|Projected Price to Earnings Singular Genomics Systems, Inc.|OMIC - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Singular Genomics Systems, Inc.|OMIC - Operating profit before deduction of amortization|Earnings per share for the trailing year Singular Genomics|OMIC - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months singulargenomics.com|OMIC - Net earnings per share growth this year|Expected net earnings per share growth next year Singular Genomics Systems
Initial company analysis:singulargenomics.com, OMIC
The development of G4 sequencing systems through partnerships with research institutes is directly reflected in the year-over-year EPS dynamics for Singular Genomics Systems (OMIC) over the last 12 months. This indicator measures the rate of change in earnings per share using a TTM rolling window to smooth out quarterly volatility. The calculation is based on a comparison of current annual earnings with the same period last year. The growth of this metric confirms the effectiveness of the synergy from joint projects; however, the trend warrants caution when assessing the business's market valuation.
Competitor analysis
TEM: Earnings per share for the last twelve months|QGEN: Net earnings per share (EPS TTM)|Ionis Pharmaceuticals, Inc. (IONS) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Repligen Corp.|RNA: Earnings per share for the trailing year|Net earnings per share for the last 12 months CRSP (CRISPR Therapeutics AG)|WGS (genedx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RARE (Ultragenyx)|Net earnings per share for the trailing year Beam Therapeutics Inc|Sarepta Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Twist Bioscience Corp|10x Genomics, Inc. (TXG) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NTLA|Earnings per share for the last twelve months Stoke Therapeutics, Inc.|Net earnings per one share for the last twelve months BioLife Solutions Inc BLFS|Earnings per share for the last twelve months Wave Life Sciences Corp (WVE)|Net earnings per share for the last 12 months Maze Therapeutics Corp MAZE|Net earnings per share (EPS TTM) SION (Sionna Therapeutics Inc)|Net earnings per share for the last four quarters primemedicine.com (PRME)|Taysha Gene Therapies, Inc. - Net earnings per share (EPS TTM)|uniQure NV (QURE) - Net earnings per share for the last 12 months|MeiraGTx PLC (MGTX) - Earnings per share for the last twelve months|RGNX - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months SLDB|OCGN: Earnings per share for the trailing year|Earnings per share for the last twelve months PacBio (PACB)|Net earnings per share for the last four quarters Benitec Biopharma Inc|Design Pharma - Net earnings per share for the last 12 months|Rocket Corp (RCKT) - Net earnings per one share for the last twelve months|FDMT - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Lexeo Therapeutics LXEO|KRRO (korrobio.com) - Net earnings per share for the last 12 months|EDIT: Earnings per share for the last four quarters|SLN (Silence Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ProQR Therapeutics NV PRQR|Earnings per share for the last twelve months Codexis, Inc. (CDXS)|Net earnings per share for the last 12 months sangamo.com SGMO|Earnings per share for the last twelve months Nautilus Bio NAUT|Net earnings per share for the last four quarters Metagenomi Inc. (MGX)|DTIL - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Generation Bio Co.|Boundless Bio, Inc. (BOLD) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Exicure|IMNN (Imunon Inc) - Net earnings per share (EPS TTM)|RXi Pharmaceuticals (PHIO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) MBIO|Net earnings per share for the last 12 months transcodetherapeutics.com RNAZ|Net earnings per share (EPS TTM) BNGO (Bionano Genomics)|APDN: Earnings per share for the last 12 months|BLUE - Earnings per share for the last twelve months|IPA (ImmunoPrecise Antibodies) - Earnings per share for the last 12 months|OMGA: Net earnings per share (EPS TTM)|Regulus (RGLS) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Syros Pharmaceuticals|telesisbio.com (TBIO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) TCON|Net earnings per share for the last four quarters Unity Biotechnology Inc.
